Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT03595150
PHASE2/PHASE3
Diclofenac for Prevention of Post-ERC Pancreatitis
Sponsor: Karolinska Institutet
View on ClinicalTrials.gov
Summary
The study aims at assessing the effectiveness of Diclofenac for prevention of post-ERCP pancreatitis. It will be undertaken embedded in the Swedish national register for Gallstone surgery and ERCP (GallRiks). Patients are randomised to Diclofenac prior to the ERCP or no prophylaxis. GallRiks is used to identify which patients fulfill the eligibility criteria and which patients develop pancreatitis after the ERCP.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
1000
Start Date
2026-01-01
Completion Date
2028-12-31
Last Updated
2025-08-13
Healthy Volunteers
No
Conditions
Interventions
DRUG
Diclofenac
Diclofenac rectally given before the ERCP to prevent pancreatitis